- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Goldman Sachs Bets Large on Biocon Biosimilars
Biocon Biologics nets a $150 million investment from Goldman Sachs to further its development and marketing of biosimilars.
Biosimilar company Biocon Biologics said it will receive a $150 million investment from Goldman Sachs.
Biocon said in a statement that it regarded the capital infusion as a sign of confidence from the global investment community in the potential of the Bangalore, India-based company.
“This capital injection by Goldman Sachs will enable us to make prudent investments in [research and development], high-quality manufacturing, as well as establish a global commercial footprint,” said Christiane Hamacher, PhD, CEO of Biocon Biologics.
Biocon markets 2 biosimilars in the US: a trastuzumab (Ogivri) and a pegfilgrastim (Fulphila), both in partnership with Mylan. The companies have also launched an insulin glargine (Semglee), which references Lantus.
The product is essentially a biosimilar, but was not approved as one owing to the regulatory pathway followed. Biocon and Mylan are seeking biosimilar and interchangeable status for Semglee. Interchangeable status would mean pharmacists could dispense it without physician involvement.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
August 22nd 2024Alvotech reported $236 million in revenue for the first 6 months of 2024, a 10-fold increase from the same period the year prior. The new figures come after the company received its first 2 FDA approvals in 2024.
